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The Immune Microenvironment of Microsatellite Instable Endometrial 
Cancer 
 
Janelle Beth Pakish, M.D., M.S. 
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Limited treatment options are available for patients with advanced and recurrent 
endometrial cancer (EC) should standard chemotherapy fail. Recent studies in other 
tumor types have shown that tumors with high microsatellite instability (MSI-H) have 
increased immunogenicity and response to immunotherapy treatments compared to 
microsatellite stable (MSS) tumors.  Patients with MSI-H EC may also benefit from these 
therapies; however, the tumor immune microenvironment in MSI-H EC has not yet been 
well described. 
In order to evaluate the immune microenvironment of MSI-H EC, multiple 
approaches were used, including analysis of large publically available datasets and 
detailed characterization of patient tumor samples.  Uterine cancer data from The Cancer 
Genome Atlas (TCGA) was used to study immune-related gene expression in MSI-H EC 
compared to MSS EC at both the individual gene and pathway level.   Fluorescent 
multiplexing immunohistochemistry (IHC) was used to evaluate differences in immune 
cell populations using tumor specimens from these two groups followed by automated 
multispectral imaging and analysis to visualize and quantify staining in the tumor 
epithelial and stromal compartments.  Nonparametric Mann-Whitney test was used to 
determine statistical significance (p value <0.05) of positive cell counts for CD3, CD4, 
CD8, CD103, CD68, CD11c, granzyme B, and PD-L1 between the groups. 
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Overall, MSI-H EC demonstrated increased immune activation compared to MSS 
EC.  Using TCGA data, MSI-H (n=118) EC showed overall activation of the granzyme B 
signaling pathway compared to MSS (n=160) EC (p <0.01).  IHC analysis demonstrated 
increased granzyme B+ cells (114.9 cells/mm2 vs 75.8 cells/mm2; p<0.01), activated 
cytotoxic T cells (CTLs) (45.6 cells/mm2 vs 28.0 cells/mm2; p<0.01), and PD-L1+ cells 
(291.6 cells/mm2 vs 240.5 cells/mm2; p<0.01) in the stroma of MSI-H versus MSS ECs.  
The number of granzyme B+ and activated cytotoxic T cells was also increased in the 
tumor epithelial compartment of MSI-H compared to MSS ECs.  There was no difference 
in the other markers evaluated.  
In conclusion, the immune microenvironment differs in MSI-H ECs with 
increased tumor immunogenicity compared to MSS tumors.  Elevated PD-L1 expression 
also suggests immune response inhibition in these tumors, and patients with this subset of 
tumors are likely candidates for immune checkpoint blocking agents.   
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Chapter 1: Introduction  
OVERVIEW 
As the most frequent gynecologic malignancy in the Unites States, endometrial 
cancer (EC) is predicted to affect approximately 60,000 women in 2016 with a subsequent 
10,500 EC related deaths (1).  Due to the presence of early warning symptoms, such as 
postmenopausal bleeding, the majority of women with EC are diagnosed at an early stage 
(70%).  Disease is typically localized to the uterus and has an associated 5-year overall 
survival (OS) of nearly 95% (2).  In fact, most women with early stage disease are cured 
with hysterectomy alone (2). While the initial prognosis is positive, a subset of these 
patients will recur. Additionally, those women who have recurrent disease, or who are 
found to have advanced stage, have a worse prognosis with 5-year OS ranging from only 
20-66% (3).  Given the poor outcomes for recurrent and advanced disease, it is critical to 
identify key molecular subtypes amenable to targeted therapeutic strategies and to identify 
sub-groups that are more likely to recur.   
Many factors are known to increase the risk of EC.  Primarily, these risk factors 
include those that increase estrogen exposure like estrogen only hormone replacement 
therapy, obesity, early menarche, and late menopause.  Inherited genetic syndromes, such 
as Lynch syndrome (LS), can also lead to increased risk of endometrial cancer.  LS is an 
autosomal dominantly inherited disorder of a germline mutation in a DNA mismatch repair 
(MMR) gene that cause DNA MMR deficiency.  These DNA MMR deficiency genes 
include: MLH1 (human mutL homolog 1), MSH2 (human mutS homolog 2), MSH6 (human 
mutS homolog 6), PMS2 (human postmeitotic segregation 2), and EPCAM (epithelial cell 
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adhesion molecule).   Secondary to MMR deficiency, LS is associated with an elevated 
risk of developing EC, as well as, colorectal, ovarian, stomach, renal, ureteral, biliary tract, 
and central nervous system cancers (4). The lifetime risk of EC in women with LS is 60%, 
and about half will present with EC or ovarian cancer as their initial cancer diagnosis (4, 
5). The specific risk of EC with MSH6 mutations is 73%, 31% with MLH1, and 29% with 
MSH2 (6), and more than 80% of LS-related ECs demonstrate endometrioid histology (4).   
Overall, EC includes a wide spectrum of clinical, pathological, and molecular 
features that have been used to classify EC into different subtypes.  Traditionally this 
included subdivision of EC into two categories (7).  Type 1 tumors are the most common 
and consist mostly of the early stage and good prognosis cases described earlier.   These 
tumors are also typically estrogen-dependent, of endometrioid histology, and low grade. 
Type 2 tumors, on the other hand, tend to be more aggressive, are of non-endometrioid 
histology, and have an overall worse prognosis.  The Cancer Genome Atlas (TCGA) for 
uterine cancer created an integrated genomic characterization to provide a more 
sophisticated view of EC subtypes.  The initial analysis of uterine cancer TCGA data 
included all tumors (multiple histologic subtypes together) and identified four unique 
groups characterized by somatic nucleotide substitutions (8).  These groups included an 
ultramutated group of polymerase ε (POLE) mutations, a hypermutated group containing 
tumors with microsatellite instability (MSI), a low mutational rate group (copy-number 
low), and a copy-number high group comprising mostly non-endometrioid histology 
tumors. Later studies were conducted to characterize the molecular mechanisms underlying 
the observed clinical heterogeneity and identify subtypes at higher risk of recurrence.  Liu 
et al. utilized the TCGA uterine data along with a separate validation tumor sample set to 
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perform molecular subtyping of endometrioid EC (9).  In this analysis, they found four 
discreet subtypes of endometrioid EC that were defined by clinical, pathological, and 
mutational patterns.  Cluster I consisted of tumors with low grade and stage along with 
increased expression of estrogen and progesterone receptors.  Cluster II also contained low 
grade and stage tumors, but demonstrated worse survival and significantly more beta-
catenin (CTNNB1) mutations.  Cluster III and IV on the other hand, contained more 
advanced stage and advanced grade tumors, as well as, more P53 mutations.  Myosin 1 
(MYH1) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations were also 
more frequently seen in Cluster III, and cytokine IK (IK) mutations were limited to Cluster 
IV.  MSI was seen in all clusters, but represented half of cases in both Cluster III and IV 
and Lynch-related cases were not specifically examined. The different mutational profiles 
of these four clusters are demonstrated in Figure 1.  Although our understanding of EC 
biology has advanced with these molecular classifications, these molecular fingerprints 
have not yet been translated to success using current targeted agents.   
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Figure 1. TCGA uterine cancer clusters by gene expression.   
Distinct gene expression profiles are seen among the four endometrioid endometrial 
cancer subtypes. Red signifies normalized mRNA expression levels greater than the mean 
and green indicates those below the mean.  Reproduced with permission from Oxford 
University Press: Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati r, 
Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W, Clinical Significance of 
CTNNB1 Mutation and WnT Pathway Activation in Endometrioid Endometrial 
Carcinoma. J Natl Cancer Inst, 2014;106 (9).   
 
LYNCH SYNDROME AND MICROSATELLITE INSTABILITY 
One molecular subset of EC that has recently gained attention as a potential target 
for specific therapeutics is defined by microsatellite instability.  This group includes both 
inherited LS-related and sporadic MSI EC, which both result from defects in DNA MMR. 
Damage to this pathway results in deficient repair of base pair mismatches that occur 
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during DNA replication (4).  This deficiency then leads to multiple errors in areas of 
repetitive DNA sequences, known as microsatellites, resulting in microsatellite instability 
in these tumors (4). In sporadic MSI tumors, sporadic hypermethylation of the MLH1 
promoter results in MMR deficiency and high microsatellite instability (MSI-H), and these 
are sometimes referred to as Lynch-like tumors.  This hypermethylation specifically 
inactivates the MLH1 gene through epigenetic silencing.  Overall, MSI-H tumors account 
for 23-30% of ECs (both sporadic and Lynch-related) (10-13).   LS accounts for 2-6% of 
ECs overall and 30% of MSI-H ECs are secondary to LS (4, 13, 14) 
The clinical relevance of MSI status has recently been recognized, as MSI-H colon 
and gastric tumors have shown an overall survival advantage over microsatellite stable 
(MSS) tumors (15, 16). In colon cancer, this survival benefit is limited to those patients not 
receiving adjuvant chemotherapy (17).  Several studies have shown that adjuvant 5-
fluorouracil is associated with improvement in overall survival in only MSS tumors and 
not MSI-H, and demonstrates the use of MSI as a marker of non-response to therapy (17, 
18). However, it is not clear whether MSI-H ECs, including Lynch-related ECs, 
demonstrate this same survival benefit or whether it may be used as biomarker for therapy 
(19-21).  Identifying a treatment targeting this molecular subgroup of EC could help to 
improve responses in some recurrent and advanced cases.    
TREATMENT OF ADVANCED ENDOMETRIAL CANCER 
For those patients with advanced and recurrent EC that fail treatment with standard 
chemotherapy, response to subsequent chemotherapy is poor, and attempts to identify 
promising targeted agents have been limited. Combination chemotherapy in advanced 
cases has response rates (RR) of 40-60%, and decreases further to 9-30% if initial therapy 
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is unsuccessful (22-24).  Those with recurrent EC that are not candidates for radiation 
therapy also have similar responses to combination chemotherapy. In order to improve RR, 
attempts to identify drugs that target specific molecular alterations have been made, but 
with very limited success.  As previously shown and then confirmed in the TCGA, EC has 
frequent phosphatase and tensin homolog (PTEN) mutations and aberrant regulation of the 
phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) 
signaling pathway.  This pathway has been targeted with mTOR inhibitors in those with 
recurrent and metastatic EC and shown partial responses of 9-14% and stable disease 
ranging from 40-70% (25-27). However, no complete responses have been demonstrated.  
Additionally, limited success of less than 15% RR has been seen with other targeted agents, 
thus far (28, 29). As of now, no recommended targeted therapies exist for EC despite 
attempts to identify subgroups that would benefit from such therapy. 
CANCER IMMUNOTHERAPY  
Immunotherapy has recently emerged as a promising treatment strategy in multiple 
tumor subtypes and could improve treatment outcomes in advanced and recurrent EC.  
Tumors demonstrating increased tumor immunogenicity are particularly good candidates 
for this type of treatment.  The tumor specific somatic mutational rate is thought to correlate 
with the number of tumor specific neoantigens produced, based on prediction models (30). 
These neoantigens are then recognized by the immune system as non-self and can trigger 
an anti-tumoral immune response with immune cell infiltration into these tumors and 
cytotoxic T lymphocyte (CTL) activation (30).  The ability to then harness and amplify this 
anti-tumor immune response is the basis of cancer immunotherapy.   
Mounting an Anti-Tumor Immune Response 
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Tumor infiltrating lymphocytes (TILs), including CTLs, have been recognized as a 
key indicator of anti-tumor immune response.  In fact, CTLs are the major effectors of the 
adaptive anti-tumor immune response.  Naïve CD8+ T cells are transformed into CTLs 
through T cell receptor (TCR) recognition of antigen presentation by major 
histocompatibility (MHC) class I molecules.  This activation also requires co-stimulation 
by the T cell associated receptor CD28 binding to either the CD80 or CD86 ligand on the 
antigen presenting cell (31).  CTLs then direct specific anti-tumor activity through the 
release of cytoloytic granules, such as granzyme B and perforin.  This was initially 
supported in part by the association of TILs and CTLs with improved survival in multiple 
tumor types (32-34).  While the field of cancer immunotherapy has grown exponentially 
in recent years, few studies have focused specifically on endometrial cancer. As a result, 
our understanding of mechanisms of immunotherapy must borrow heavily from other 
tumor types.    
However, CTLs are not the only cells that participate in anti-tumor immune 
response.  Many different immune cell populations are involved in both the anti-tumor and 
immune evasion responses. Natural killer (NK) cells are a component of the innate immune 
response and, like CTLs, also have directed cytolytic activity against tumor cells (35).  
CD4+ T helper cells, in contrast, contribute to the anti-tumor response by enhancing 
activation of CTLs, as well as, NK cells and macrophages (36). Successful cancer 
immunotherapy requires tipping the balance to favor anti-tumor response while blocking 
mechanisms of tumor evasion.  A summary of the immune cells and corresponding 
receptors evaluated in this thesis is depicted in table 1.  
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Table 1. Common immune cells and immune cell markers seen in the tumor 
immune microenvironment. 
 
Immune Cell Function Markers 
T cell Lymphocyte that participates 
in cell mediated immunity and 
adaptive immune response 
General: CD3 
CD8+  T cell T lymphocyte that participates 
in the adaptive immune 
response with tumor directed 
killing after transformation to 
CTL 
General: CD3, CD8 
Activated: Granzyme B 
Intraepithelial: CD103 
Helper T cell Specific T cell that participates 
in the adaptive immune 
response through cytokine 
release which activates B cells, 
T cells, macrophages, and NK 
cells 
General: CD3, CD4 
Natural Killer Cell Cytotoxic lymphocyte that 
participates in the innate 
immune response  
General: NKp46 
Activated: Granzyme B 
Macrophage Antigen presenting cell and 
phagocyte 
General: CD68 
Dendritic Cell Antigen presenting cell General: CD11c 
 
Mechanisms of Tumor Evasion 
Despite the presence of CTLs in tumors with increased immunogenicity and tumor 
directed immune activation, these tumors are still capable of evading the immune response.  
Tumor associated macrophages (TAMs) are thought to play a critical role in the 
development of immune evasion.  These macrophages are induced by cytokines in the 
tumor microenvironment (IL-10 and IL-4) to undergo transformation into type II 
macrophages (37).  This specific macrophage subset has limited antigen presenting 
capacity and instead suppresses T cell function, thus creating a pro-tumorigenic 
environment (37).   CD4+ T cells can also be transformed into T regulatory cells which 
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have immunosuppressive activity, that is in contrast to the T helper cell function mentioned 
previously (38).   
 Immune evasion is also attributed to upregulation of immune checkpoints on 
immune cells that work to dampen the immune response.  Normally this pathway helps to 
prevent autoimmune tissue destruction; however, the tumor microenvironment hijacks this 
immune regulation to prevent ongoing tumor directed immune attack. The most common 
immune checkpoints expressed are CTLA-4 (cytotoxic T lymphocyte associated protein 4) 
and PD-1 (programmed death 1).  Both CTLA-4 and PD-1 function in distinct biological 
pathways and demonstrate different patterns of expression (39).  Figure 3 summarizes the 
CTLA-4 and PD-1 immune cell inhibitor action.   The CTLA-4 receptor is expressed 
immediately upon T cell activation, and then competitively binds the T-cell co-stimulatory 
signal (CD80 and CD86), to reduce the magnitude of the immune response.  PD-1 receptor 
expression, in contrast, is delayed as it requires gene transcription.  The PD-1 inhibitor 
pathway also acts more locally within the tumor microenvironment as the ligand for PD-1 
(PD-L1) can be expressed by both tumor and infiltrating immune cells (39).  Upregulation 
of PD-L1 expression by both the tumor and infiltrating immune cells is another adaptation 
for immune evasion (40).  In fact, PD-L1 expression has been shown to be upregulated in 
tumor cells that are immediately adjacent to TILs and it has been suggested that TILs 
induce their own inhibition through cytokine release that result in upregulation of PD-L1 
(40).  
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Figure 2. Immune checkpoints help to regulate immune responses and can be 
utilized by the tumor microenvironment to dampen and inhibit tumor directed 
immune responses.   
CTLA-4 and PD-1 are commonly expressed immune checkpoints.  B27 is expressed by T 
cells and binds CD80 and CD86 as a co-stimulatory signal to T cell antigen recognition. 
CTLA-4 is also expressed by activated T cells and competitively binds the T cell co-
stimulatory ligands CD80 and CD86 leading to deamplification of the immune response. 
Additionally, the PD-1 receptor expression by T cells acts within the tumor 
microenvironment to inhibit the immune response.  It binds PD-L1 and PD-L2 expressed 
by both the tumor and other immune cells.  
 
Expression of Immunotherapy Targets 
Expression of PD-L1 differs among tumor types, and remains an area of continued 
investigation. A summary of the PD-L1 expression studies discussed below can be found 
in Table 2.  In a study by Taube et al, PD-L1+ tumors were defined as those with at least 
5% tumoral expression and expression was characterized across tumor types.  This study 
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showed a wide range of expression, with castration-resistant prostate cancers (CRPC) 
having no PD-L1+ cases compared to 90% positivity of kidney cancers (41).  Additionally, 
about 50% of melanoma and non-small cell lung cancer (NSCLC) cases were PD-L1+.  
This same study also found positive expression of PD-L1 on infiltrating immune cells in 
half of melanomas, NSCLCs, and colorectal cancers (CRC).  Another study evaluating 
pretreatment PD-L1 expression found PD-L1 expression in several tumor types to be more 
common on infiltrating immune cells than on the tumor cells themselves (42).  The 
percentage of PD-L1+ tumor cells ranged from 1% (CRC) to 24% (NSCLC).  In contrast, 
the percentage of PD-L1+ immune cells ranged from 12% (pancreatic cancer) to 36% 
(melanoma).  
Monoclonal antibodies against both CTLA-4 and PD-1, as well as against PD-L1, 
have shown efficacy in multiple cancer types, however, the potential value of PD-L1 
expression as biomarker for response is still uncertain (43-45).  In a study of nivolumab 
(anti-PD-1 antibody) across tumor types, objective response was correlated with tumoral 
PD-L1 expression but not PD-L1 expression by infiltrating immune cells (41).  Treatment 
with MPDL3280A (anti-PD-L1 antibody) has also demonstrated objective responses of 13-
26% among a variety of different malignancies (42).  Although the RR alone was not overly 
impressive in this study, the majority of responders had durable responses lasting at least 
one year.  In contrast to nivolumab treatment, response to MPDL3280A was significantly 
correlated with PD-L1 expression on immune cells rather than tumoral PD-L1 expression.  
Given this early conflicting data that may reflect the differences in the immune 
microenvironment among tumor types, the use of PD-L1 expression as a biomarker for 
response to immune checkpoint inhibiting agents requires additional investigation.  
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Table 2. Immunotherapy literature summary 
Abbreviations: NSCLC, non-small cell lung cancer; CRPC, castration-resistant prostate 
cancer; overall response rate, ORR 
 
CD8+ T Cell Subpopulations 
In addition to the presence of TILs, CTLs, and immune checkpoint expression, 
other CD8+ T cell subpopulations have been investigated and associated with improved 
survival and tumor immunogenicity.  In high grade serous ovarian cancer (HGSOC), the 
presence of CD8+ T cells within the tumor epithelium has been associated with improved 
prognosis (46).  Retention of these CD8+ T cells to the tumor epithelium is thought to be 
mediated by expression of CD103 (αE/β7 integrin) on the T cell which binds to E-cadherin 
in the tumor epithelium (47).  Furthermore, high prevalence of CD8+CD103+ T cells in 
HGSOC correlates with enhanced survival (48).  This interaction of CD103 with the E-
PD-L1 Studies 
 
Author(y) 
Cancer Type Marker  
PD-L1 Expression 
 
Findings 
Ref 
Taube 
(2014) 
Melanoma 
NSCLC 
Colorectal 
CRPC 
PD-L1+ tumor 
or immune 
cells (≥5% of 
cells) 
Tumor Cells  
Melanoma (47%) 
NSCLC (53%) 
Colorectal (13%) 
CRPC (0%) 
 
Immune Cells  
Melanoma (50%) 
NSCLC (53%) 
Colorectal (50%) 
CRPC (0%) 
Treatment with 
nivolumab 
(anti-PD1) 
-PD-L1+ tumor cells 
associated with ORR 
(p=0.03) and clinical 
benefit (p=0.01).  
-PD-L1+ immune cells 
associated only with 
clinical benefit (p=0.04) 
41 
Herbst 
(2014) 
Melanoma 
NSCLC 
Colorectal 
Renal Cell 
Head and Neck 
PD-L1+ tumor 
or immune 
cells (≥5% of 
cells) 
Tumor Cells  
Melanoma (5%) 
NSCLC (24%) 
Colorectal (1%) 
Renal Cell (10%) 
Head and Neck (19%) 
 
Immune Cells  
Melanoma (36%) 
NSCLC (26%) 
Colorectal (35%) 
Renal Cell (25%) 
Head and Neck (28%) 
Treatment with 
MPDL3280A 
(anti-PD-L1) 
-PD-L1+ immune cells 
associated with response 
to treatment (p=0.01) 
-PD-L1+ tumor cells not 
associated with response 
(p=0.08) 
42 
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cadherin ligand has also been proposed as a mechanism for tumor specific recognition by 
CTLs (49).   
IMMUNOTHERAPY IN MSI-H TUMORS 
Some MSI-H tumor types, have been reported to be more immunogenic and also 
demonstrated increased expression of immune checkpoints.  MSI-H CRCs have a higher 
density of TILs and CTLs and increased immune checkpoint expression compared to MSS 
colorectal cancers (50, 51).  Specifically, Llosa et al. showed MSI-H CRCs have increased 
CTL infiltration and activation within the epithelial component of the tumor, the tumor-
associated stroma, and at the invasive front (50).  Along with this pro-inflammatory 
environment, expression of multiple immune checkpoint markers were also increased in 
MSI-H colorectal cancers, including PD-1, PD-L1 , CTLA-4 , LAG-3 (lymphocyte-
activation gene 3), and IDO (Indoleamine 2,3-dioxygenase).   It is suggested that the 
presence of CTLs and increased immune checkpoint expression in tumors are key 
indicators that immunotherapy may have increased efficacy in MSI-H tumors.  
Due to these reports of enhanced immunogenicity, the efficacy of immunotherapy 
in MSI-H tumors is now being evaluated in clinical studies. Specifically, the observation 
of increased immune checkpoint expression in colorectal MSI-H tumors has led to trials of 
immune checkpoint blockade. Pembrolizumab, a monoclonal antibody targeting PD-1, was 
recently studied in a phase 2 trial of progressive and metastatic MSI-H CRC. This trial 
showed improved immune-related objective response rates (encompasses patterns of 
response specific to immunotherapy) in MSI-H CRC compared to MSS CRC (52).  Of 
interest, a third arm of the study included patients with MSI-H non-CRC tumors, including 
two women with EC, and also demonstrated improved response to anti-PD-1 therapy. Of 
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the two EC patients, one had a complete response and the other a partial response to anti-
PD-1 therapy.  Updates to this study, with the inclusion of additional MSI-H EC patients, 
were recently presented at the 2016 Society of Gynecologic Oncology Annual Meeting 
(53).  Response rates of 56% were seen in the MSI-H EC population (n=9), including one 
complete response and four partial responses, and additional studies in MSI-H and MSS 
ECs are currently being planned.     
IMMUNE MICROENVIRONMENT OF MSI-H ENDOMETRIAL CANCER 
While our knowledge of the immune microenvironment in cancer has grown 
overall, our understanding in EC has lagged behind. A few studies have evaluated the 
relationship of the immune microenvironment and survival in EC.  Kondratiev et al, 
demonstrated an association with improved overall survival for patients with tumors 
containing at least 10 CD8+ T cells at the invasive front (54).  Higher numbers of TAMs 
are also found in the stroma compared to the tumor epithelium in EC overall, but has not 
been associated with tumor stage or disease status (55). 
A small number of limited studies have shown conflicting data regarding the 
immune microenvironment and immunogenicity of MSI-H EC and these studies have not 
addressed Lynch-related cases specifically (56-58).  One recent study by Howitt et al 
predicted the neoantigen load of MSI-H EC to be 7-fold higher compared MSS EC using 
TCGA data (56).   Additionally, this study used immunohistochemistry to characterize 
further parameters of the immune microenvironment.  However, it is important to note that 
the number of cases used in this study was small and immunohistochemistry evaluation 
was limited to one high powered field per case.  Yet, this limited study found a significantly 
higher number of CD3+ and CD8+ TILs in MSI-H and POLE compared to MSS ECs.  
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Lastly, PD-L1 expression on immune cells of the MSI-H/POLE tumors was higher than in 
MSS, but there was no difference in tumoral PD-L1 expression.  Another study by van 
Gool et al, also showed higher CD8+ T cell infiltration in both the intraepithelial and 
intrastromal regions of MSI-H compared to MSS tumors (59).  This same study also 
evaluated immune gene expression using TCGA and found increased CD8A and IFNγ 
expression in MSI-H tumors, but no significant difference in perforin or granzyme B 
expression.   
These early studies offer hints that the immune microenvironment of MSI-H ECs 
may be similar to that seen in MSI-H CRC with increased immunogenicity and immune 
cell infiltration.   However, the specifics of the immune environment of MSI-H EC and 
how this may differ from MSS EC still remain largely unknown. Therefore, there is a 
critical need to understand the immune microenvironment of MSI-H EC to determine if 
this subtype is amenable to treatment with immunotherapy.  It is also unknown if Lynch 
syndrome-related MSI-H (LS MSI-H) ECs have a comparable immune microenvironment 
to sporadic MSI-H EC.  Our central hypothesis is that MSI-H ECs will have an altered 
immune microenvironment compared to MSS ECs, and demonstrate increased immune 
checkpoint expression.  To address this question we first used TCGA uterine data to 
evaluate differences in gene expression and global pathway alterations between MSI-H and 
MSS ECs.  We then performed immunohistochemistry (IHC) multiplexing with advanced 
quantitation methods to further characterize the differences in immunologic markers 
between these tumor types.  
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Chapter 2: Methods 
TCGA ANALYSIS 
 In collaboration with the Bioinformatics Resource Group at The University of 
Texas MD Anderson Cancer Center, TCGA uterine cancer RNA sequencing (RNAseq) 
version 2 dataset was used to evaluate gene expression differences between MSI-H and 
MSS EC.  From this data, 118 MSI-H cases and 160 MSS cases were identified and used 
for the analysis.  RNAseq read counts were converted into integer values via rounding in 
Excel.  Genes with a median read count of less than 10 for both groups were filtered out.  
This left 15393 genes out of an initial 20531 genes for evaluation.  Next, significance 
analysis of microarrays (SAM) (Stanford University, CA) was used to detect statistically 
significant differences in gene expression between the two groups as two class, unpaired 
samples.  Only genes with a q value < 0.05 were extracted for further pathway evaluation.   
The false discovery rate was accounted for by using the q value that signifies that 5% of 
significant results will result in false positives.  
 Ingenuity Pathway Analysis (IPA) (Qiagen, CA) was then used to investigate 
pathway alterations between MSI-H and MSS EC.  The differentially expressed genes 
obtained from SAM analysis, as described above, were uploaded to IPA to create a Core 
Analysis, which was used to investigate differences in canonical pathways in MSI-H versus 
MSS tumors.   
 A more specific TCGA analysis focused on immune-related and inflammatory 
genes was later conducted with recently released updated Level 3 uterine cancer data.  In 
Level 3 expression data, gene and mRNA levels RNAseq data is post  normalization and 
processed to allow for interpretive analysis (60).  This particular analysis evaluated mRNA 
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level  differences in a more specific immune and inflammatory gene panel as described by 
Lal et al (61).  The list of queried genes can be seen in Table 3.   
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Table 3. Immune related genes investigated with TCGA uterine data 
 
Gene ID Gene Name 
ACTB Beta actin 
CCL11 Chemokine ligand 11 
CCL2 Chemokine ligand 2 
CCL5 Chemokine ligand 5 
CD247 CD247 molecule 
CD274 CD274 molecule 
CD276 CD276 molecule 
CD3D CD3d molecule, delta 
CD3E CD3e molecule, epsilon 
CD3G CD3g molecule, gamma 
CD4 CD4 molecule 
CD80 CD80 molecule 
CD86 CD86 molecule 
CD8A CD8a molecule 
CD8B CD8b molecule 
CTLA4 Cytotoxic T-lymphocyte associated protein 4 
CX3CL Chemokine ligand 1 
CXCL10 Chemokine ligand 10 
CXCL9 Chemokine ligand 9 
FOXP3 Forkhead box P3 
GNLY Granulysin 
GZMB Granyzme B 
HLA-A Major histocompatibility complex, class I, A 
HLA-B Major histocompatibility complex, class I, B 
HLA-C Major histocompatibility complex, class I, C 
HLA-DMA Major histocompatibility complex, class II, DM alpha 
HLA-DMB Major histocompatibility complex, class II, DM beta 
HLA-DOA Major histocompatibility complex, class II, DO alpha 
HLA-DOB Major histocompatibility complex, class II, DO beta 
HLA-DPA1 Major histocompatibility complex, class II, DP alpha 1 
HLA-DPB1 Major histocompatibility complex, class II, DP beta 1 
HLA-DQA1 Major histocompatibility complex, class II, DQ alpha 1 
HLA-DQA2 Major histocompatibility complex, class II, DQ beta1 
HLA-DRA Major histocompatibility complex, class II, DR alpha  
HLA-DRB5 Major histocompatibility complex, class II, DR beta 5 
ICAM1 Intercellular adhesion molecule 1 
ICOS Inducible T cell co-stimulator 
IFNG Interferon gamma 
IL10 Interleukin 10 
IL12RB2 Interleukin 12 receptor, beta 2 
IL17A Interleukin 17A 
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Gene ID Gene Name 
IL18RAP Interleukin 18 receptor accessory protein 
IL7R Interleukin 7 receptor 
IRF1 Interferon regulatory factor 1 
KLRK1 Killer cell lectin-line receptor subfamily K, member 1 
LAG3 Lymphocyte-activation gene 3 
MADCAM1 Mucosal vascular addressin cell adhesion molecule 1 
MICB MHC class I polypeptide-related sequence B 
PDCD1 Programmed cell death 1 
PDCD1LG2 Programmed cell death 1 ligand 2 
PROCR Protein C receptor, endothelial 
RAET1E Retinoic acid early transcript 1E 
RAET1G Retinoic acid early transcript 1G 
STAT1 Signal transducer and activator of transcription 1 
STAT3 Signal transducer and activator of transcription 2 
TBX21 T-box 21 
TNFRSF14 Tumor necrosis factor receptor superfamily, member 14 
TNFSF4 Tumor necrosis factor superfamily, member 4 
ULBP1 UL16 binding protein 1 
ULPB2 UL16 binding protein 2 
ULPB3 UL16 binding protein 3 
VCAM1 Vascular cell adhesion molecule 1 
VTCN1 V-set domain containing T cell activation inhibitor 1 
 
REAGENTS AND ANTIBODIES 
The OpalTM IHC kit (PerkinElmer, MA) was used for fluorescent IHC multiplexing.  
The kit included fluorescent tyramide signal amplification (TSA) reagents, amplification 
diluent, and DAPI (4',6-diamidino-2-phenylindole).   
 The following antibodies were used for fluorescent IHC  multiplexing:  CD3 
(1:900, clone SP7, Thermo Scientific, MA), CD4 (1:450, clone 4B12, Thermo Scientific, 
MA), CD8 (1:400, clone 4B11, Leica, UK), CD11c (1:1000, clone 5D11, Leica, UK), 
Granzyme B (1:300, clone 11F1, Leica, UK), CD103 (1:5000, clone EPR4166, Abcam, 
MA), CD68 (1:500, clone KP1, Biogenex, CA), PD-L1 (1:1600, clone E1L3N, Cell 
Signaling, MA), and NKp46 (1:4000, clone aa55-104, Lifespan Biosciences, WA). 
 20 
 
Antibody diluent was used for antibody dilution (Invitrogen, CA).  10% normal goat serum 
blocking solution was used for background slide blocking (Life Technologies, CA).  Citrate 
buffer of pH 6.0 was used for antigen retrieval (Poly Scientific, NY).  Secondary anti-
mouse or anti-rabbit antibody horseradish peroxidase (HRP) polymer conjugate was used 
prior to fluorophore application (Invitrogen, CA).  Coverslips were mounted to slides with 
aqueous mounting solution (Thermo Scientific, MA) 
TUMOR SPECIMENS AND CLINICAL DATA 
Endometrial cancer specimens were identified from the gynecologic oncology 
archived tumor bank and Lynch syndrome patient registry in accordance with Institutional 
Review Board (IRB) protocols.  In total, 59 MSI-H EC specimens were identified from 
2000-2015.  The majority of cases were from 2012-2015, but this time frame was 
expanding to include additional cases from the Lynch syndrome patient registry given the 
rarity of these tumors and the need for available primary tumor specimens. These cases 
were then matched approximately 1:2 to MSS cases; resulting in identification of 108 MSS 
cases.  Matching was done according to histology, tumor grade, tumor stage, age at 
diagnosis, and body mass index (BMI) at time of diagnosis, as available.   Clinical data for 
the cohort was abstracted from the medical record. Of the cases identified, nine specimens 
were unable to be located.  When the missing specimen was an MSI-H case, its 
corresponding matched MSS cases were also filtered out from the dataset.  If no MSS cases 
were found for any one MSI-H case, the MSI-H case was also removed from the dataset.  
Archived formalin-fixed paraffin embedded (FFPE) tumors were cut into 4 micron sections 
by the research histology core.    
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DETERMINATION OF MSI STATUS AND MMR DEFECT 
MSI Testing 
 MSI status was determined clinically by a method developed by the Molecular 
Diagnostic Laboratory at MD Anderson Cancer Center (MDACC) that has been previously 
described (62). This data was reported in the medical record and collected retrospectively. 
Briefly, MSI testing was performed following extraction of DNA from FFPE tumor and 
normal tissue.  A polymerase chain reaction (PCR) based method was used for analysis 
followed by capillary electrophoretic detection of microsatellite markers.  Seven 
microsatellite markers were used in this method.  These markers included BAT 25, BAT 
26, BAT 40, D2S123, D5S346, D17S250, and TGFBR2.  The number of tumor 
microsatellite repeats for each of the markers was compared to normal tissue from the same 
case.  A tumor was considered to have microsatellite instability if three or more of the 
seven markers demonstrated allelic shift.  
DNA MMR Deficiency by IHC 
 The process for identification of DNA MMR deficiency was developed by the 
Molecular Diagnostic Laboratory at MDACC as previously described (62), and the 
information was collected retrospectively from the pathology report.  
Immunohistochemistry was performed on FFPE tumor blocks to assess expression of 
MMR proteins (MLH1, MSH2, MSH6, PMS2).  Lack of protein expression of MSH2, 
MSH6, or PMS2 in the tumor, by this method, was considered probable Lynch syndrome.  
For those with MLH1 loss by IHC, MLH1 promoter methylation was performed.  Those 
cases showing MLH1 loss by IHC and without MLH1 promoter methylation were 
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classified as probable Lynch syndrome.  IHC was used to define probable Lynch syndrome 
as germline MMR gene mutation testing was not available on all case.   
Promoter Methylation 
 MLH1 promoter methylation status was also determined via a method developed 
by the MDACC Molecular Diagnostic Laboratory and collected retrospectively from the 
pathology reports in the electronic medical record.  Briefly, bisulfate was used to treat 
extracted DNA from FFPE samples.  This resulted in conversion of cytosine to uracil in 
unmethylated cases. PCR amplification of methylated and unmethylated MLH1 promoter 
region was performed and these sequences were labeled fluorescently and detected via 
capillary electrophoresis as previously described (63).   
IMMUNOHISTOCHEMISTRY STAINING 
Antibody Optimization 
 Prior to initiation of IHC multiplexing, each antibody of interest was tested to 
determine optimal antibody dilution and antigen retrieval (AR) temperature.  A set of serial 
dilutions for each antibody was performed based on published IHC data and the 
manufactures recommendations to establish the best dilution and AR temperature.      
Multiplexing  
Multiple panels were required to enable evaluation of nine total markers.  Some markers 
were repeated on multiple panels to allow for colocalization studies. The individual panels 
are described in detail below. Details of the IHC multiplexing protocol follow the 
multiplexing panel descriptions.   
Multiplexing (6-plex) Panel #1 
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For the first IHC multiplexing panel, the following antibodies were used: anti-Granzyme 
B for activated CTLs and NK cells, anti-CD8 for CD8+ T cells, anti-NKp46 for NK cells, 
anti-CD68 for macrophages, anti-PD-L1 for PD-L1 expressing cells, and DAPI. The order 
of antibody application and associated fluorescent TSA reagent was as follows: (1) anti-
Granzyme B/Cyanine 3 (Cy3), (2) anti-CD8/Fluorescein (FITC), (3) anti-CD68/Cyanine 
5.5 (Cy5.5), (4) anti-PD-L1/Cyanine 3.5 (Cy3.5), (5) anti-NKp46/Cyanine 5 (Cy5), and (6) 
DAPI.  The staining sequence is also represented in Table 4 along with the specific 
antibody dilution and manufacturer.   
Multiplexing (5-plex) Panel #2 
 For the second multiplexing panel, a slightly modified set of reagents had been 
updated by the manufacturer.  The new fluorescent TSA reagents had undergone further 
stringent evaluation and optimization by the manufacturer for IHC multiplexing use; 
however, all IHC processing steps remained the same.  Names of the new fluorophores 
(shown below and in Table 4) reflect the excitation wavelength in nanometers (nm).  The 
following antibodies were used for this multiplexing set: anti-CD3 for all T cells, anti-CD4 
for helper T cells, anti-PD-L1 for PD-L1 expressing cells, and anti-CD11c for dendritic 
cells.  The order of antibody application and associated fluorescent TSA reagent was as 
follows: (1) anti-CD3/520 nm, (2) anti-CD4/540 nm, (3) anti-PD-L1/620 nm, (4) anti-
CDllc/690 nm, and (5) DAPI.   
Multiplexing (3-plex) Panel #3 
 Antibodies for this set included: anti-CD8 for CD8+ T cells and anti-CD103 for 
intraepithelial T cells.   The order of antibody application and associated fluorescent TSA 
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reagent was as follows: (1) anti-CD103/520 nm, (2) anti-CD8/620 nm, and (3) DAPI.  
Table 4 contains the specific antibody conditions and staining sequence.  
 
Table 4. Fluorescent IHC multiplexing antibodies and conditions. 
 
Abbreviations: Conc, concentration; AR, antigen retrieval; TSA tyramide signal 
amplification. 
. 
Immunohistochemistry Protocol 
The OpalTM fluorescent multiplexing kit from Perkin Elmer (Waltham, MA) was 
used according to the manufacturer’s protocol as previously described by Stack et al (64).  
 
Primary Antibody 
 
Company 
 
Host 
 
Conc. 
AR 
Temp 
(ᵒC) 
 
TSA 
 
Order 
Multiplexing Panel #1       
Granzyme B Leica mouse 1:300 96 Cy3 1 
CD8 Leica mouse 1:400 96 FITC 2 
CD68 Biogenex mouse 1:500 120 Cy5.5 3 
PD-L1 Cell 
Signaling 
rabbit 1:1600 96 Cy3.5 4 
NKp46 Lifespan 
Biosciences 
rabbit 1:4000 120 Cy5 5 
DAPI      6 
Multiplexing Panel #2       
CD3 Thermo 
Scientific 
rabbit 1:900 96 520 1 
CD4 Thermo 
Scientific 
mouse 1:450 96 540 2 
PD-L1 Cell 
Signaling 
rabbit 1:1600 96 620 3 
CD11c Leica mouse 1:1000 96 690 4 
DAPI      5 
Multiplexing Panel #3       
CD103 Abcam rabbit 1:5000 96 520 1 
CD8 Leica mouse 1:400 96 620 2 
DAPI      3 
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Details are given below and a flow chart of the steps can also be seen in Figure 3. Antibody 
details including dilutions, manufacturers, and AR conditions are shown in Table 4.  
 
 
Figure 3. Flow chart of fluorescent IHC multiplexing method.   
 
STEP 1: DEPARAFFINIZATION 
Deparaffinization was performed by submerging slides into three successive 
containers of xylene for 10 minutes each.   A series of ethanol solutions was then used to 
rehydrate the tissue as follows: 100% for five minutes, 95% for five minutes, and 70% for 
 26 
 
two minutes.  Following rehydration, the slides were washed in distilled water (dH2O) for 
two minutes then in Tris-Buffered Saline with 0.05% Tween 20 (TBST) for two minutes.   
After deparaffinization, care was taken to ensure slides were kept in light blocking 
containers throughout the remaining IHC process to limit unnecessary light exposure.  
STEP 2: ANTIGEN RETRIEVAL 
 Next, AR was carried out by placing the slides in citrate buffer (pH 6.0) and heating 
the slides via a decloaking chamber for 15 minutes.  The set temperature for AR was 
determined based on laboratory optimization and antibody manufacturers’ 
recommendations.   
STEP 3: WASH 
 After heating was completed, the slides were removed from the decloaking 
chamber and cooled for 20-30 minutes to room temperature.  The slides were then washed 
in dH2O for two minutes followed by TBST for two minutes.  For the NKp46 antibody, an 
additional wash of 1% hydrogen peroxide for 10 minutes followed by a TBST was for two 
minutes was used to decrease endogenous peroxidase activity.  This step was not required 
for any of the other antibodies.   
STEP 4: BLOCKING 
 Slides were then removed from the wash solution.  Excess liquid was wiped from 
the slides and the tissue was demarcated using a hydrophobic barrier pen.  Sufficient 10% 
normal goat serum (Life Technologies, CA) blocking solution was applied to cover the 
tissue (75-100 microliters (μL)) and slides were incubated in a humidified chamber. 
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STEP 5: PRIMARY ANTIBODY 
 After 30 minutes, the blocking solution was removed from the slides and primary 
antibody was applied to the tissue.  Again, sufficient diluted antibody solution (75-100 μL) 
was used to cover the tissue.  Slides incubated with the primary antibody in a humidified 
chamber at 4ᵒC overnight.   For the anti-CD103 antibody, the slides were incubated at room 
temperature for 30 minutes in a humidified chamber before proceeding with washing as 
described below. All other antibodies used the overnight incubation procedure.   
 After overnight incubation (approximately 16 hours), primary antibody was 
removed from the slides.   The slides were then washed in TBST with agitation and at room 
temperature for two minutes.  This wash process was repeated three times.   
STEP 6: SECONDARY HRP CONJUGATE 
 Slides were wiped of excess liquid and 100 μL of diluted secondary HRP conjugate 
(Invitrogen, CA) was applied to the tissue.  Depending on the host species of the primary 
antibody, either mouse or rabbit secondary HRP conjugate was used.  Slides were 
incubated in a humidified chamber at room temperature for 10 minutes.  The slides were 
again washed three times in TBST with agitation at room temperature for two minutes.   
STEP 7: TSA APPLICATION 
 The fluorophore labeled TSA reagent was first resuspended in 150 μL of dimethyl 
sulfoxide (DMSO) and then diluted 1:50 in 1X Amplification Diluent (Perkin Elmer, MA) 
to produce the working TSA solution.  Slides were wiped of excess liquid and 75-100 μL 
of TSA working solution (Perkin Elmer, MA) was applied to the tissue.  The slides were 
incubated in a humidified chamber at room temperature with the TSA solution for 10 
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minutes.  The slides were again washed in TBST for two minutes at room temperature three 
times. A different fluorophore labeled TSA solution was used for each antibody.     
STEP 8: ANTIGEN RETRIEVAL/HEATING 
 Slides were again heated in citrate buffer of pH 6.0 for 15 minutes in a decloaking 
chamber.  Following heating, the slides were left to cool to room temperature for 20-30 
minutes in the citrate buffer.  The slides were then washed with dH20 for two minutes, 
followed by TBST for two minutes at room temperature. The specific temperature was 
determined by the conditions needed for AR of the next antibody to be applied.  For the 
last heating step in the multiplexing sequence, 96ᵒC was used.   
 After step 8, the process was repeated beginning at step 3 for each subsequent 
antibody used.  After the final antibody and fluorophore labeled TSA solution was applied, 
the process proceeded to step 9.   
STEP 9: DAPI 
 DAPI solution from the OpalTM fluorescent multiplexing kit (PerkinElmer, MA) 
was then applied.  This solution was diluted two drops in one mL of TBST prior to 
application.  100 μL of the diluted DAPI solution was applied to the tissues and incubated 
in a humidified chamber at room temperature for five minutes.  DAPI was then removed 
and the slides were washed in dH20 for two minutes.  A drop of aqueous mounting solution 
(Thermo Scientific, CA) was applied to the slides for cover slip mounting.  The slides were 
stored in a dark container at 4ᵒC.   
Control Slides 
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 Individual fluorophore control slides were prepared for each antibody and 
associated fluorophore labeled TSA reagent in order to create a spectral library and to 
determine imaging exposure times for each fluorophore.  This was accomplished using 
IHC steps 1-8 as described above.  Similarly, a DAPI only slide was stained using the 
described IHC steps 1-3.  DAPI was then applied as described in step 9.  Lastly, an 
unstained slide of uterine tissue was deparaffinized and heated as above and mounted to be 
used for determination of autoflourescence during the imaging analysis process.   
IMAGING AND DATA ANALYSIS 
The imaging and inForm® analysis portion of the project was performed with 
assistance from the MDACC Flow Cytometry and Cellular Imaging Facility. 
Imaging 
 Due to the multiple antibodies and multiple fluorophores used for several markers 
on each slide, unique imaging was required. This multispectral imaging was accomplished 
with the Vectra® 2 automated system (PerkinElmer, MA).  This system allows for the 
capture of tissue images at multiple wavelengths and is able to analyze multiple markers, 
or antibodies, on a single slide.  Analysis of multiple markers on a single slide also enables 
colocalization studies.  
Initial low power images at 4X were obtained for all tissue on each slide. Up to 30 
high power field images were then randomly captured at 20X through automation by the 
Vectra® system.  These fields were captured based on highest density of tumor cells in the 
images.  A series of sample EC multiplex images from the data set were used to define 
areas of tumor, stroma, and normal tissue that was then applied to create a pattern 
recognition algorithm for high power field acquisition. For the multiplexing sets, four 
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filters were used to capture images (DAPI, Cy3, FITC, and Cy5).  Exposure times were 
determined for each of the filters using a representative individually stained slide, and 
subsequently used for acquisition of all images.  
inForm® Analysis 
Once images were obtained, the inForm® system version 2.1.5430.24864 was used 
to create a spectral library of each of the fluorophores.  Images from the single fluorophore 
slides were used for this library.  This allowed for unmixing of the individual fluorophores, 
and confirmed unique staining for each of the antibodies.  
This same system was also used to identify tissue regions of interest and to score 
positive cellular tagging of the antibodies of interest.  A series of multiplex images were 
randomly selected to provide a sample set of images to define areas of tumor epithelium, 
tumor associated stroma, myometrium and blank space. This sample set of images was then 
used to train the inForm® system in pattern recognition of these different tissue segments.  
The training algorithm also included DAPI and each spectral component, specific to the 
multiplex staining panel, to create the tissue segmentation algorithm that was applied to all 
images.  The system was subsequently able to classify the pixels within the training set 
with 85-94% accuracy.   
 Next, DAPI staining was used to identify nuclei within each of the tissue 
compartments, and to obtain total cell counts with in each of the compartments. The DAPI 
staining was also used as a reference to determine cellular cytoplasm and membrane 
segmentation based on the inForm® algorithm.  Thresholds and scoring for positively 
staining cells for each of the antibodies were determined through manual examination of 
each antibody among the EC multiplex training images.  This examination included 
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identifying a fluorescent pixel intensity that accurately identified positive staining cells 
across the training set within the cellular compartment (cytoplasm or membrane) unique to 
each of the antibodies. Signal thresholds were determined using average fluorescent pixel 
density for each of the fluorophores and corresponding antibodies.  Thresholds, along with 
cellular compartment of interest, are as follows: 
 Multiplexing Panel #1: Granzyme B/Cy3 - membrane (score >3), CD8/FITC - 
membrane (score >2), PD-L1/Cy3.5 - cytoplasm (score >5), NKp46/Cy5 - 
membrane (score >1), and CD68/Cy5.5 – cytoplasm (score >1).  
 Multiplexing Panel #2: CD3/520 nm – membrane (score >0.83), CD4/540 nm - 
membrane (score >0.33), PD-L1/620 nm - cytoplasm (score >2.5), and CDllc/690 
nm - membrane (score >0.2). 
 Multiplexing Panel #3: CD103/520 nm – membrane (score >2.0) and CD8/620 nm 
- membrane (score >4.5). 
For each antibody, signal greater than the determined threshold was considered 
positive staining.    
 An inForm® algorithm was then run based on the previously defined tissue 
segmentation, identification of individual cells and corresponding cellular compartments, 
and the scoring system for each of the antibodies of interest.  The generated composite 
images were reviewed manually, and the reviewer was blinded to MSI status during this 
review.  In the manual review, images that were determined to have inaccurate tissue 
segmentation were added to the training set of images to improve segmentation accuracy.  
However due to the wide variation of tissue architecture, 100% accuracy was unable to be 
obtained and those images that appeared to have gross segmentation inaccuracy were 
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excluded from the analysis.  Overall, there were on average 16 images analyzed per 
specimen (range 1-35).  A small subset of slides required reimagining due to poor 
identification of tissue and tumor by the automated system, and in these cases, more than 
30 images were allowed in repeat image capture.  This accounts for the increased number 
of images in two cases with greater than 30 images.  
Some cases were not included in the overall analysis due to problems with tissue 
quality or imaging.  This occurred because of tissue degradation (likely due to multiple 
rounds of heating from the multiplexing process), lack of tumor cells present in that section, 
or lack of tumor images captured by the automated system from inaccurate tissue 
segmentation for image acquisition.  If the removed case was MSI-H, the corresponding 
MSS matched pairs were also removed.  Additionally, if a MSS case that was removed 
resulted in no matched cases for a MSI-H case, the MSI-H case was also removed from the 
analysis. 
The number of positive staining cells for each of the antibodies was determined per 
millimeter squared (mm2) within the tumor epithelium and tumor associated stroma for 
each of the cases using code written in SAS version 9.2 (Cary, NC) by collaborator Gary 
Chisholm (Programmer/Analysis, Department of Gynecologic Oncology and Reproductive 
Medicine). 
  
STATISTICAL ANALYSIS 
 Statistical analysis was performed using Stata version 14.1 (College Station, TX).  
The Mann-Whitney and Kruskal-Wallis tests were used to compare demographic data 
between the groups as indicated. For overall comparison of immune cellular markers 
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between MSI-H and matched MSS cases, the nonparametric Mann-Whitney test was used.  
The Mann-Whitney test was also used for comparison of sporadic MSI-H and matched 
MSS cases, as well as, MSI-H Lynch cases compared to MSS matches. A p value of < 0.05 
was used to signify statistical significance.  Box plots were also created to compare 
differences among mRNA levels, positive staining cell counts, and percent positive 
staining cells.  The upper border of the box represents the third quartile, the lower border 
the first quartile, and the line the median.  The whiskers are defined using the Tukey box 
plot method where they represent 1.5 times the upper and lower interquartile range.   
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Chapter 3: Results 
TCGA ANALYSIS 
 Using TCGA uterine cancer RNAseq data, global gene expression was compared 
for 118 MSI-H endometrioid endometrial cancers and 160 microsatellite stable tumors.  
Analysis of the differential gene expression revealed 2148 upregulated and 2645 
downregulated genes in MSI-H tumors compared to MSS tumors. Further examination of 
global pathway alterations using IPA demonstrated significant activation of the granzyme 
B signaling pathway in MSI-H compared to MSS tumors (p<0.01), but not in other 
immune- or inflammatory-related pathways.  Genes in the granzyme B pathway include 
but are not limited to: granzyme B, perforin, caspase 3, caspase 8, caspase 9, apoptotic 
peptidase activating factor, DNA fragmentation factor, endonuclease G, and cytochrome 
c.  Upon cytotoxic cell activation, the granzyme B pathway triggers cellular apoptosis of 
target cells and increased pathway activation suggests increased CTL activity in MSI-H 
tumors. 
A panel of specific immune- and inflammatory-related genes was also compared 
using TCGA RNAseq data.   Of the 64 genes evaluated, mRNA levels in MSI-H tumors 
were significantly elevated for 11 genes (p<0.01).  These genes included multiple T cell 
effector (CD8a, ICOS, MICB, ULBP1), T cell attractant chemokine (CXCL9), immune 
checkpoint (LAG3), NK cell effector (ULBP2, ULBP3), immune cytokine (IFNG), 
regulatory T cell (FOXP3), and beta actin (ACTB) genes.  A subset of the significant 
mRNA comparisons between MSI-H and MSS EC is represented in Figure 4. MSI-H 
tumors also had significantly decreased mRNA levels of an eosinophil chemotactic 
cytokine gene (CCL11) (p<0.01).  
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Figure 4. MSI-H ECs demonstrate increased expression of multiple T cell effector 
genes compared to MSS EC.   
Analysis of RNAseq TCGA uterine cancer data comparing log2 mRNA level differences 
in MSI-H and MSS EC for (A) FOXP3, (B) CD8A, (C) IFNG, (D) LAG3, (E) CXCL9, 
and (F) ICOS represented by box plots.   
 
SPECIMENS 
 Analysis of EC cases was conducted using specimens from the gynecologic 
oncology archived tumor bank and Lynch syndrome patient registry. In total, 59 MSI-H 
cases were identified and matched approximately 1:2 to 108 MSS cases.  Of the MSI-H 
cases, 20 were found to have IHC defects in MMR genes consistent with probable Lynch 
syndrome and this group was used for the LS MSI-H sub-analysis.  37 MSI-H cases 
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demonstrated sporadic promoter methylation of MLH1 and were used for the sporadic 
MSI-H sub-analysis.  One case had loss of MSH2 and MSH6 on IHC, but no germline 
deleterious mutations of DNA MMR genes. One case had unknown specific protein loss, 
but was positive for microsatellite instability with allelic shift in 5 of 7 microsatellite 
markers.  These last two cases were included only in the overall MSI-H versus MSS 
analysis. Among the 20 LS MSI-H cases, IHC loss of primary MMR proteins were as 
follows: 3 (15.0%) in MLH1, 14 (70.0%) in MSH2, 3 (15.0%) in MSH6, and no cases 
showed loss of PMS2 or EPCAM.   
DEMOGRAPHICS 
 There were no significant differences in characteristics used for case matching 
(histology, age at diagnosis, BMI, stage, and grade) as shown in Table 5.  Some data could 
not be obtained for a small number of cases in the MSI-H cohort, almost exclusively Lynch 
Syndrome EC cases. The majority of these cases were obtained from a Lynch syndrome 
patient registry where specimens included those collected from outside institutions, which 
had more limited associated clinical information.  Of these, 11 cases were missing details 
of depth of myometrial invasion and 12 were missing LVSI information.  As comparison 
of depth of invasion and LVSI were not primary objectives, and these cases were not 
excluded from the cohort. In addition, 2 cases had unknown grade (both LS MSI-H) and 5 
had unknown stage (All LS MSI-H).  However, these cases were matched according to the 
data available and were included in the analysis given the limited number of cases of the 
LS MSI-H subtype.  
The majority of cases were stage IA in both groups (MSI-H 59.3% vs MSS 66.7%; 
p=0.80) with about 13% representing more advanced stage III or IV cases (MSI-H 13.6% 
 37 
 
vs MSS 13.0%; p = 0.80).  The majority of cases were grade 2 in each of the groups (MSI-
H 69.5% vs MSS 75.9%; p=0.63), and more aggressive grade 3 cases made up 17.0% in 
the MSI-H and 13.0% in the MSS cohort.  As most cases were stage IA, only 25.4% had 
myometrial invasion equal to or greater than 50% in the MSI-H and 26.9% in the MSS 
cases. Lastly, there was a significant difference in lymphovascular space invasion (LVSI) 
between the two groups with more MSS cases having LVSI present (67.6%) than that seen 
in the MSI-H (39.0%) cases (p=0.02).   
Table 5. Baseline patient characteristics by MSI-H and MSS status.  
 
 MSI-H (N=59) MSS (N=108) P value 
Mean Age (y) 63.0 59.5 0.84 
Mean BMI (kg/m2) 34.3 36.5 0.19 
Histology, N (%)   0.60 
   Endometrioid 55 (93.2) 106 (98.2)  
   Undifferentiated 1 (1.7) 1 (0.9)  
   Mixed 3 (5.1) 1 (0.9)  
Stage, N (%)   0.80 
IA 35 (59.3) 72 (66.7)  
IB 8 (13.6) 17 (15.7)  
II 3 (5.1) 5 (4.6)  
III/IV 8 (13.6) 14 (13.0)  
Unknown 5 (8.5) --  
Grade, N (%)   0.63 
     1 6 (10.2) 12 (11.1)  
     2 41 (69.5) 82 (75.9)  
     3 10 (17.0) 14 (13.0)  
     Unknown 2 (3.4) --  
Depth of Myometrial 
Invasion, N (%) 
  0.46 
No invasion 8 (13.6) 24 (22.2)  
< 50% 25 (42.4) 55 (50.9)  
≥ 50% 15 (25.4) 29 (26.9)  
Unknown 11 (18.6) --  
LVSI, N (%)   0.02* 
Present 23 (39.0) 73 (67.6)  
Absent 24 (40.7) 33 (30.6)  
Unknown 12 (20.3) 2 (1.9)  
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Abbreviations: BMI, body mass index; kg/m2, kilograms per meter squared; LVSI, 
lymphovascular space invasion   
IMMUNE MICROENVIRONMENT OF MSI-H ENDOMETRIAL CANCER COMPARED TO MSS 
TUMORS 
 The immune microenvironment in MSI-H versus MSS EC was examined using 
three fluorescent IHC multiplexing panels. The first panel evaluated positive staining of 
CD8 (CD8+ T cells), granzyme B (activated CTLs or NK cells), CD68 (macrophages), PD-
L1 (immune checkpoint ligand), and NKp46 (NK cells).  Staining with the NKp46 antibody 
was difficult to optimize and ultimately resulted in nonspecific staining.  As a result, this 
marker could not be analyzed. The second panel measured positive staining for CD3 
(general T cell marker), CD4 (CD4+ T cells), PD-L1 (immune checkpoint ligand), and 
CD11c (dendritic cell marker).  Finally, the third panel evaluated positive staining of 
CD103 (intraepithelial T cell or dendritic cell marker) and CD8 (CD8+ T cells). 
Representative images for each of the multiplexing panels are demonstrated in Figure 5.   
Markers repeated in multiple panels (PD-L1 and CD8) demonstrated substantial variation 
in overall total positive cell counts in subsequent multiplexing panels. However, as noted 
in Methods, batch effects for multiplex staining (due to differences in conditions between 
panels) make it necessary for comparison of these markers to only be performed within a 
multiplexing batch.  PD-L1+ staining showed a 1.2-1.4 fold difference in the stroma and a 
1.4-2 fold difference in the tumor epithelial compartment. While CD8+ staining had a 1.2-
1.3 fold difference in the stroma and a 1.5-2.1 fold difference in the tumor epithelial 
compartment. Additionally, the counts in the tumor epithelial compartment may be less 
reliable due to the low overall positive cell counts which are reflected in the wider variation 
of fold difference within the tumor epithelial compartment.  
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Figure 5. Fluorescent IHC multiplexing panel images.  
(A) Representative image of IHC multiplexing panel 1 including: CD8 (green), Granzyme 
B (red), CD68 (orange), PD-L1 (magenta), and DAPI (blue). (B) Representative image of 
IHC multiplexing panel 2 including: CD3 (green), PD-L1 (red), CD4 (magenta), CD11c 
(white), and DAPI (blue). (C) Representative image of IHC multiplexing panel 3 including: 
CD 103 (green), CD8 (red), and DAPI (blue).  S indicates peritumoral stroma; G indicates 
tumor glandular epithelium.  
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 Details of the number of positively stained cells per marker within both the stromal 
and tumor epithelial compartments for the entire cohort are shown in Table 6 to enable 
comparison of the relative abundance of positive staining across different tissue 
compartments and markers (within each individual multiplex panel, as indicated on the 
table). Among all MSI-H tumors, the mean number of granzyme B+, PD-L1+, and CD4+ 
staining cells were significantly higher within the tumor associated stroma. As other studies 
have looked at the percentage of PD-L1+ cells, this was also assessed in our cohort to allow 
for comparison across studies.  The percentage of PD-L1+ staining stromal cells was also 
significantly increased in the MSI-H cases (59.2% vs 49.0%; p<0.01), but not in the tumor 
epithelium (5.4% vs 3.8%; p=0.26) when compared to MSS EC (Figure 6A and 6B).  There 
was no statistically significant difference seen in the mean number of stromal cells staining 
positive for CD3, CD8, CD103, CD68, or CD11c between MSI-H and MSS tumors.  
In evaluating the tumor epithelial compartment, the mean number of granzyme B+ 
staining cells in the MSI-H group was significantly higher, while the mean number of 
CD68+ staining cells within the tumor epithelial compartment was significantly lower in 
the MSI-H versus MSS cases.  There was no significant difference seen in mean number 
of cells staining positive for CD3, CD4, CD8, CD103, CD11c, or PD-L1 between MSI-H 
and MSS tumors in the tumor epithelial compartment.   
 
Table 6. Comparison of positive staining cell counts between MSI-H and MSS ECs 
 
 
Marker 
All MSI-H EC 
Mean No of positive 
cells/mm2 (range) 
MSS EC 
Mean No of positive 
cells/mm2 (range) 
 
P value 
Stromal Compartment    
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CD81 50.7 (0-180.1) 39.4 (0-342.6) 0.06 
Granzyme B1 114.9 (0.1-440.4) 75.8 (0-657.2) <0.01* 
CD681 29.1 (0-156.6) 22.9 (0-127.9) 0.86 
PD-L11 291.6 (107.6-434.2) 240.5 (28.6-408.3) <0.01* 
CD32 89.5 (0.3-282.2) 69.7 (3.4-179.0) 0.05 
CD42 25.4 (0-82.4) 17.8 (0.2-76.1) 0.02* 
CD11c2 22.1 (0-133.9) 17.4 (0-133.3) 0.49 
CD1033 7.9 (0-107.4) 4.8 (0-128.8) 0.30 
Tumor Epithelial 
Compartment  
   
CD81 7.9 (0-53.5) 5.1 (0-38.4) 0.07 
Granzyme B1 38.9 (0-391.0) 32.6 (0-433.8) <0.01* 
CD681 1.8 (0-8.5) 2.8 (0-19.2) 0.03* 
PD-L11 21.3 (0-243.8) 15.4 (0-214.2) 0.29 
CD32 51.5 (0.1-349.6) 37.9 (1.0-236.1) 0.23 
CD42 25.6 (0-255.8) 17.1 (0-130.4) 0.31 
CD11c2 8.9 (0-83.1) 11.1 (0-87.7) 0.27 
CD1033 23.5 (0-111.6) 17.7 (0-92.5) 0.48 
1Multiplex panel 1; 2Multiplex panel 2; 3Multiplex panel 3; *p<0.05. Abbreviations: 
MSI-H, high microsatellite instability; MSS, microsatellite stable; EC endometrial 
cancer. 
 
 
 
 
 
Figure 6. MSI-H ECs show increased stromal PD-L1 expression compared to MSS 
ECs.  
(A) Box plot representing the percentage of PD-L1+ cells within the peritumoral stroma 
compartment of MSI-H vs MSS EC.  (B) Box plot of the percentage of PD-L1+ cells 
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within the tumor intraepithelial compartment of MSI-H vs MSS EC. The center line of 
the box plot indicates the median. *p value <0.05.  Abbreviations: MSI-H, high 
microsatellite instability; MSS, microsatellite stable.  
 
 
 Comparison of marker colocalization in each tissue compartment is shown in Table 
7. Co-staining of CD8+ and granzyme B+ cells was analyzed to assess the number of 
activated CTLs within the two groups.  In all MSI-H tumors, there were significantly more 
activated CTLs in both the stromal and in the tumor epithelial compartments. There was 
also a significant increase seen in colocalization of PD-L1+ and CD11c+ staining cells (PD-
L1+ dendritic cells) among the stroma in all MSI-H versus MSS EC, but not in the tumor 
epithelial compartment.  Stromal colocalization staining for activated CTLs and PD-L1+ 
dendritic cells is shown in Figures 7A and 7C. Colocalization of CD3+ and CD4+ staining 
cells, denoting T helper cells, demonstrated a significant increase in mean number of cells 
between all MSI-H and MSS in the stroma, but not within the tumor epithelial 
compartment.  Lastly, no difference was seen in colocalization of CD103+ and CD8+ 
positive cells (intraepithelial CD8+ cells) or of PD-L1+ and CD68+ staining cells (PD-L1+ 
macrophages) in either of the compartments in all MSI-H versus MSS EC.  Stromal PD-
L1+ macrophages are represented in Figure 7B.  
 
Table 7. Comparison of co-staining positive cell counts between MSI-H and MSS 
ECs 
 
Marker 
All MSI-H EC 
Mean No of positive 
cells/mm2 (range) 
All MSS EC 
Mean No of positive 
cells/mm2 (range) 
 
P value 
Colocalization in Stromal 
Compartment 
   
CD81/Granzyme B1 45.6 (0.7-179.1) 28.0 (0-228.4) <0.01* 
PD-L11/CD681 25.1 (0-148.4) 15.6 (0-93.8) 0.49 
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CD32/CD42 24.9 (0-82.3) 17.4 (0.2-75.7) 0.02* 
PD-L12/CD11c2 6.7 (0-66.3) 4.3 (0-97.9) 0.01* 
CD83/CD1033 5.22 (0-83.0) 2.92 (0-94.0) 0.26 
Colocalization in Tumor 
Epithelial Compartment 
   
CD81/Granzyme B1 5.7 (0-53.5) 2.3 (0-11.6) 0.03* 
PD-L11/CD681 0.5 (0-5.5) 0.2 (0-1.8) 0.74 
CD32/CD42 25.0 (0-255.8) 16.8 (0-130.3) 0.25 
PD-L12/CD11c2 0.4 (0-11.3) 0.2 (0-1.6) 0.14 
CD83/CD1033 1.7 (0-43.3) 0.51 (0-1.5) 0.20 
1Multiplex panel 1; 2Multiplex panel 2; 3Multiplex panel 3; *p<0.05. Abbreviations: 
MSI-H, high microsatellite instability; MSS, microsatellite stable; EC, endometrial 
cancer. 
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Figure 7.  MSI-H ECs have increased stromal activated CTLs and PD-L1+ dendritic 
cells compared to MSS ECs. 
(A) Box plots demonstrating the number of positive cells per mm2 of activated CTLs (co-
staining of CD8 and granzyme B), (B) PD-L1+ macrophages (co-staining of PD-L1 and 
CD68), and (C) PD-L1+ dendritic cells (co-staining of CD11c and PD-L1) in the 
peritumoral stroma. The center box plot line indicates the median positive cell count. *p 
value <0.05. Abbreviations: CTL, cytotoxic T lymphocyte; MSS, microsatellite stable; 
MSI-H, high microsatellite instability. 
 
SPORADIC MSI-H ENDOMETRIAL CANCER 
 A secondary sub-analysis was then performed to assess differences in the immune 
microenvironment of sporadic MSI-H EC compared to MSS tumors (excluding LS MSI-
H cases).  This analysis included only MSI-H tumors with MLH1 promoter methylation 
compared to matched MSS tumors. The overall mean values for each marker are depicted 
in Table 8.  Within this subgroup, the number of granzyme B+, CD3+, and CD4+ staining 
cells within both the tumor associated stroma and the tumor epithelial compartments was 
higher among the sporadic MSI-H versus MSS cases.  This was in comparison to only 
increased stromal and tumor epithelial granzyme B+ staining cells and stromal CD4+ 
staining cells in all MSI-H versus MSS cases. The percentage of PD-L1+ staining cells 
(61.1% vs 45.3%; p<0.01) was significantly higher in the stromal compartment for 
sporadic MSI-H versus MSS cases like that seen in all MSI-H cases (Fig 8A), as well as 
within the tumor epithelial compartment (sporadic MSI-H 6.3% vs MSS 2.3%; p=0.03) 
(Fig 8B).  As seen in all MSI-H versus MSS cases, there was no difference in the mean 
number of positive staining cells within the stroma for CD8, CD68, CD11c, or CD103 in 
sporadic MSI-H compared to MSS EC.  In the tumor epithelial compartment, mean positive 
staining cell counts for CD8, CD68, CD11c, or CD103 were also not significantly different 
between sporadic MSI-H versus MSS cases.  
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Table 8. Comparison of positive staining cell counts between sporadic MSI-H and 
MSS ECs.   
 
Marker 
Sporadic MSI-H EC 
Mean No of positive 
cells/mm2 (range) 
MSS EC 
Mean No of positive 
cells/mm2 (range) 
 
P value 
Stromal Compartment     
CD81 36.9 (0-133.7) 45.3 (0-342.6) 0.62 
GranzymeB1 107.4 (12.3-377.9) 84.1 (0-657.2) 0.02* 
CD681 36.6 (0.5-156.6) 20.9 (0-127.9) 0.25 
PD-L11 297.3 (112.7-433.9) 225.9 (28.6-408.3) <0.01* 
CD32 88.1 (11.7-233.7) 65.9 (3.4-179.0) 0.03* 
CD42 26.6 (2.7-73.4) 16.5 (0.2-76.1) <0.01* 
CD11c2 22.8 (0-133.9) 16.5 (0-133.3) 0.21 
CD1033 7.2 (0-107.4) 5.7 (0-128.8) 0.40 
Tumor Epithelial 
Compartment 
   
CD81 5.9 (0.1-20.1) 5.5 (0-38.4) 0.30 
Granzyme B1 43.5 (0-391.0) 35.2 (0-433.8) <0.01* 
CD681 2.4 (0-8.5) 2.8 (0-19.2) 1.0 
PD-L11 25.0 (0.2-243.8) 10.0 (0-68.3) 0.02* 
CD32 56.5 (4.0-349.6) 33.3 (1.4-181.7) 0.04* 
CD42 29.7 (0.9-255.8) 14.5 (0.1-117.4) 0.04* 
CD11c2 9.9 (0-83.1) 11.6 (0-87.7) 0.63 
CD1033 24.8 (0-111.6) 18.4 (0-92.5) 0.43 
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1Multiplex panel 1; 2Multiplex panel 2; 3Multiplex panel 3; *p<0.05. Abbreviations: 
MSI-H, high microsatellite instability; MSS, microsatellite stable; EC, endometrial 
cancer. 
 
 
 
 
 
 
 
Figure 8. Sporadic MSI-H ECs show increased stromal and tumor epithelial PD-L1 
expression compared to MSS ECs.  
(A) Box plot representing the percentage of PD-L1+ cells within the peritumoral stroma 
compartment of sporadic MSI-H vs MSS EC.  (B) Box plot of the percentage of PD-L1+ 
cells within the tumor intraepithelial compartment of sporadic MSI-H vs MSS EC. The 
center line of each box plot represents the median.  *p value <0.05.  Abbreviations: MSI-
H, high microsatellite instability; MSS, microsatellite stable. 
 
 
 Table 9 compares positive co-staining cell counts within the stromal and tumor 
epithelial compartments. Sporadic MSI-H cases demonstrated an increase in stromal PD-
L1+ dendritic cells (co-staining of PD-L1 and CD11c).  This finding was similar to that 
seen in the analysis of all MSI-H versus MSS cases. There was no difference in PD-
L1+dendritic cells in the tumor epithelial compartment of sporadic MSI-H compared to 
MSS cases. There was also an increase in PD-L1+ macrophages (co-staining PD-L1 and 
CD68) in the stroma of sporadic MSI-H versus MSS cases which was not seen in the 
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analysis of all MSI-H versus MSS cases, but no differences in the intraepithelial 
compartment.  Additionally, T helper cells (co-staining of CD3 and CD4) were 
significantly increased in both the stromal and tumor epithelial compartments in sporadic 
MSI-H versus MSS cases in contrast to only in the stroma of all MSI-H versus MSS cases.  
No difference was seen in activated CTLs (co-staining of CD8 and granzyme B) in either 
the stroma or tumor epithelial compartment in contrast to that seen in all MSI-H compared 
to MSS EC. There was also no difference seen in intraepithelial CD8+ cells (co-staining of 
CD103 and CD8) in either the stromal or tumor epithelial compartments like that in all 
MSI-H versus MSS EC. Box plot comparisons of stromal CTLs, PD-L1+ macrophages, 
and PD-L1+ dendritic cells are shown in Figures 9A, 9B, and 9C.  
 
Table 9. Comparison of co-staining positive cell counts between sporadic MSI-H 
and MSS ECs. 
 
Marker 
Sporadic MSI-H EC 
Mean No of positive 
cells/mm2 (range) 
MSS EC 
Mean No of positive 
cells/mm2 (range) 
 
P value 
Colocalization in the Stromal 
Compartment 
   
CD81/Granzyme B1 32.4 (0.7-98.3) 31.0 (0-228.4) 0.41 
PD-L11/CD681 31.3 (0-148.4) 13.4 (0-93.8) 0.04* 
CD32/CD42 26.0 (2.4-73.1) 16.0 (0.2-75.7) 0.01* 
PD-L12/CD11c2 6.5 (0-66.3) 3.7 (0-97.9) 0.01* 
CD83/CD1033 4.3 (0-72.1) 3.4 (0-13.3) 0.36 
Colocalization in the Tumor 
Epithelial Compartment 
   
CD81/Granzyme B1 3.8 (0-18.4) 2.5 (0-11.6) 0.15 
PD-L11/CD681 0.7 (0-5.5) 0.2 (0-1.8) 0.05 
CD32/CD42 29.1 (0.9-255.8) 14.1 (0.1-117.2) 0.03* 
PD-L12/CD11c2 0.2 (0-1.1) 0.2 (0-1.6) 0.34 
CD83/CD1033 0.8 (0-8.3) 0.5 (0-13.3) 0.30 
1Multiplex panel 1; 2Multiplex panel 2; 3Multiplex panel 3; *p<0.05. Abbreviations: 
MSI-H, high microsatellite instability; MSS, microsatellite stable: EC, endometrial 
cancer. 
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Figure 9. Sporadic MSI-H ECs have increased stromal PD-L1+ macrophages and 
PD-L1+ dendritic cells compared to MSS ECs.  
(A) Box plots demonstrating the number of positive cells per mm2 of activated CTLs (co-
staining of CD8 and granzyme B), (B) PD-L1+ macrophages (co-staining of PD-L1 and 
CD68), and (C) PD-L1+ dendritic cells (co-staining of CD11c and PD-L1) in the 
peritumoral stroma. The center box plot line indicates the median positive cell count. *p 
value <0.05.  Abbreviations: CTL, cytotoxic T lymphocyte; MSS, microsatellite stable; 
MSI-H, high microsatellite instability. 
 
 
 LYNCH-RELATED MSI-H ENDOMETRIAL CANCER 
 Lastly, evaluation of the differences in the immune microenvironment in LS MSI-
H EC compared to matched MSS cases was conducted, and mean positive staining cell 
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counts are depicted below in Table 10.  LS MSI-H EC demonstrated a significantly higher 
mean number of granzyme B+ staining cells within the tumor associated stroma compared 
to MSS tumors as was also seen in all MSI-H and sporadic MSI-H analyses.  In contrast to 
that seen in the all MSI-H and sporadic MSI-H  versus MSS analyses, there were also a 
significantly higher mean number of CD8+ staining cells in both the stromal and tumor 
epithelial compartments among LS MSI-H versus MSS tumors. The mean number of 
CD68+ staining cells was found to be significantly reduced in both the stromal and tumor 
epithelial compartments in LS MSI-H cases compared to MSS EC, in contrast to all MSI-
H versus MSS analyses where CD68+ positive staining cells were only reduced in the tumor 
epithelial compartment.  
 There was no significant difference observed in the mean number of granzyme B+ 
staining cells within the tumor epithelial compartment between LS MSI-H and MSS EC in 
contrast to the other analyses. Mean positive staining cell counts in the stroma between LS 
MSI-H and MSS tumors showed no difference in CD3, CD4, CD103, or CD11c as 
compared to the increased CD3+ and CD4+ staining cell counts in sporadic MSI-H  versus 
MSS EC. In the tumor epithelial compartment, mean positive staining cells counts were 
not significantly different between LS MSI-H and MSS EC for CD3, CD4, CD11c, or 
CD103.  This finding was similar to that seen in the analyses of all MSI-H compared to 
matched MSS EC. There was no difference in mean PD-L1+ staining cells between the LS 
MSI-H and MSS EC in either the stromal or tumor epithelial compartments which was 
different from the increased PD-L1+ staining among stromal cells in both sporadic MSI-H 
and all MSI-H versus MSS analyses.  There was also no difference in mean percentage of 
PD-L1+ staining cells in the stroma (LS MSI-H 56.2% vs MSS 58.1%; p=0.92) and tumor 
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epithelial (LS MSI-H 3.5% vs MSS 7.2%; p=0.15) compartments in LS MSI-H versus MSS 
EC (Figure 10A and 10B).   
 
Table 10. Comparison of positive staining cell counts between LS MSI-H and MSS 
ECs.   
 
Marker 
LS MSI-H EC 
Mean No of positive 
cells/mm2 (range) 
MSS EC 
Mean No of positive 
cells/mm2 (range) 
 
P value 
Stromal Compartment    
CD81 78.4 (6.6-180.1) 25.9 (0-86.4) <0.01* 
Granzyme B1 150.7 (12.1-440.4) 58.3 (2.3-323.9) 0.01* 
CD681 14.6 (0-58.0) 28.3 (0-82.7) 0.03* 
PD-L11 281.5 (107.6-434.2) 274.0 (118.6-387.6) 0.54 
CD32 94.0 (0.3-282.2) 80.9 (17.2-167.4) 0.82 
CD42 21.7 (0-82.4) 21.8 (0.7-63.1) 1.0 
CD11c2 19.6 (0-92.1) 20.1 (0-75.5) 0.46 
CD1033 9.44 (0-85.1) 2.61 (0-34.3) 0.81 
Tumor Epithelial 
Compartment 
   
CD81 12.0 (0.6-53.5) 4.1 (0.1-14.0) 0.04* 
Granzyme B1 46.6 (0.6-248.8) 28.3 (0.1-402.6) 0.10 
CD681 0.7 (0-5.7) 3.1 (0.2-11.8) <0.01* 
PD-L11 15.6 (0-71.4) 29.2 (0.2-214.2) 0.15 
CD32 36.0 (0.1-120.0) 51.3 (1.0-236.1) 0.42 
CD42 12.6 (0-92.1) 24.9 (0-130.4) 0.23 
CD11c2 5.9 (0-24.7) 9.8 (0-39.0) 0.12 
CD1033 19.1 (0-73.9) 16.5 (0-50.8) 0.79 
1Multiplex panel 1; 2Multiplex panel 2; 3Multiplex panel 3; *p<0.05. Abbreviations: LS 
MSI-H, Lynch syndrome high microsatellite instability; MSS, microsatellite stable; EC 
endometrial cancer. 
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Figure 10. LS MSI-H ECs show no difference in stromal or tumoral PD-L1 
expression compared to MSS ECs.  
(A) Box plot representing the percentage of PD-L1+ cells within the peritumoral stroma 
compartment of LS MSI-H vs MSS EC.  (B) Box plot of the percentage of PD-L1+ cells 
within the tumor intraepithelial compartment of LS MSI-H vs MSS EC. The center line 
of each box plot represents the median.   Abbreviations: LS MSI-H, Lynch syndrome 
high microsatellite instability; MSS, microsatellite stable. 
 
 Colocalization staining is represented in Table 11.  There was a significantly higher 
mean number of activated CTLs (co-staining with CD8 and granzyme B) in LS MSI-H 
versus MSS cases with higher stromal and tumor epithelial positive cells as was seen in all 
MSI-H compared to matched MSS EC.  Within the tumoral epithelial compartment, there 
was a significant decrease in colocalization of PD-L1 and CD68 (PD-L1+ macrophages) in 
LS MSI-H compared to MSS EC, but no difference within the stroma.  Lastly, there was 
no difference seen in colocalization of PD-L1 and CD11c (PD-L1+ dendritic cells), CD3 
and CD4 (T helper cells), or CD103 and CD8 (CD8+ intraepithelial cells) in either of the 
compartments between LS MSI-H and MSS EC.  This was in contrast to the increased 
stromal PD-L1+ dendritic cells seen in the comparison of all MSI-H and sporadic MSI-H 
cases to matched MSS 
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Table 11. Comparison of co-staining positive cell counts between LS MSI-H and 
MSS ECs. 
 
Marker 
LS MSI-H EC 
Mean No of positive 
cells/mm2 (range) 
MSS EC 
Mean No of positive 
cells/mm2 (range) 
 
P value 
Colocalization in the Stromal 
Compartment 
   
CD81/Granzyme B1 68.4 (6.1-179.1) 21.4 (0.2-74.4) 0.01* 
PD-L11/CD681 4.1 (0-15.0) 7.5 (0-21.0) 0.06 
CD32/CD42 21.7 (0-82.3) 21.5 (0.7-61.8) 0.98 
PD-L12/CD11c2 7.4 (0-26.8) 6.2 (0-48.9) 0.56 
CD83/CD1033 7.45 (0-83.0) 1.68 (0-33.7) 0.73 
Colocalization in the Tumor 
Epithelial Compartment 
   
CD81/Granzyme B1 9.1 (0.3-53.5) 2.0 (0-6.9) 0.03* 
PD-L11/CD681 0.8 (0-5.0) 2.5 (0-12.0) 0.02* 
CD32/CD42 12.5 (0-47.5) 24.8 (0-130.3) 0.22 
PD-L12/CD11c2 1.2 (0-11.3) 0.1 (0-0.6) 0.23 
CD83/CD1033 4.0 (0-43.3) 0.6 (0-11.2) 0.58 
1Multiplex panel 1; 2Multiplex panel 2; 3Multiplex panel 3; *p<0.05. Abbreviations: LS 
MSI-H, Lynch syndrome high microsatellite instability; MSS, microsatellite stable; EC, 
endometrial cancer. 
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Figure 11. LS MSI-H ECs have increased activated CTLs compared to MSS ECs.  
(A) Box plots demonstrating the number of positive cells per mm2 of activated CTLs (co-
staining of CD8 and granzyme B), (B) PD-L1+ macrophages (co-staining of PD-L1 and 
CD68), and (C) PD-L1+ dendritic cells (co-staining of CD11c and PD-L1) in the 
peritumoral stroma. The center box plot line indicates the median positive cell count. *p 
value <0.05. Abbreviations: CTL, cytotoxic T lymphocyte; MSS, microsatellite stable; 
LS MSI-H, Lynch syndrome high microsatellite instability. 
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Chapter 4: Discussion 
As our understanding of the molecular and clinical heterogeneity of EC has grown, 
it is clear that a variety of therapeutic approaches will be required for successful outcomes 
both as upfront treatment and for recurrent/advanced cases.  While clinical trials of 
molecularly targeted single agents have shown disappointing results in EC, 
immunotherapy has emerged as a promising therapeutic option in multiple tumor types that 
previously had limited treatment options and poor overall prognosis (65, 66).  This 
immunologic tumor-directed response is thought to be activated by tumor-specific 
neoantigens that correlate with somatic mutational load and infiltration of CD8+ CTLs.  
This thesis sought to provide a detailed analysis of the immune microenvironment of MSI-
H EC and potential implications for response to immunotherapy.  Previous studies of the 
immune microenvironment in EC were limited and had not fully investigated sporadic 
MSI-H and LS MSI-H cases (56, 59).  These studies are critical to identifying therapeutic 
targets for advanced and recurrent EC given the limited treatment options should patients 
fail standard chemotherapy.  Currently, there are no targeted therapies in clinical use for 
molecular subsets of EC, but early studies of the immune microenvironment of MSI-H EC 
have suggested that these tumors may be more immunogenic and thus responsive to 
immunotherapy (56, 59).   
Analysis of TCGA uterine data suggested increased CTL activity in MSI-H 
compared to MSS EC.  This was shown through increased activation of the granzyme B 
pathway in MSI-H EC overall which leads to targeted cell apoptosis through CTL directed 
cytolytic activity.   Additionally, the more specific immune-related TCGA analysis 
identified upregulated mRNA levels of several T cell effector genes (CD8a, MICB, 
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CXCL9, and ICOS), that further supports at least an initial enhanced anti-tumoral response 
in MSI-H versus MSS EC.  
The comprehensive examination of the immune cell populations in MSI-H and 
MSS EC identified differences in the immune microenvironment of these two subtypes.  
MSI-H tumors had increased granzyme B+ staining cells and CTL activation within both 
the tumor epithelium and tumor associated stroma and increased Helper T cells in the 
stroma.   This suggests an immune mediated anti-tumor response in this subset of ECs. 
Stromal PD-L1 expression was also significantly increased in MSI-H EC and reflects 
immune response exhaustion and suppression.   Among all MSI-H cases, however, there 
was no significant difference in other T cell populations (CD3+, CD8+, and CD103+ 
intraepithelial T cells), CD68+ macrophages or CD11c+ dendritic cells when compared to 
MSS tumors.  
Sub-analysis of sporadic MSI-H EC also demonstrated a difference in the immune 
microenvironment compared to MSS tumors.  Sporadic MSI-H EC had increased CD3+, 
CD4+, and granzyme B+ cells in the stroma and tumor epithelium compared to MSS tumors 
reflecting an immune related response in these tumors.   Additionally, increased stromal 
and tumoral PD-L1 expression along with increased stromal PD-L1+ macrophages and PD-
L1+ dendritic cells was seen compared to MSS EC.   
Lastly, sub-analysis of LS MSI-H showed increased CTL activation compared to 
MSS EC.  This was demonstrated by increased stromal CD8+ cells, granzyme B+ cells, and 
activated CTLs in LS MI-H versus MSS EC.  CD8+ cells and activated CTLs were also 
increased in the tumor epithelial compartment in LS MSI-H versus MSS EC.  In contrast 
to the all MSI-H and sporadic MSI-H versus MSS analyses, LS MSI-H cases demonstrated 
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no difference in PD-L1+ staining in the stromal or tumor epithelial compartment compared 
to MSS EC.  Additionally, CD68+ cells were significantly reduced in the stromal and tumor 
epithelial compartments of LS MSI-H versus MSS tumors.   
Analysis of both immune cell markers and markers of immune response activity is 
needed to provide a complete view of the immune microenvironment.  Previously, studies 
in MSI-H and POLE ECs have found elevated levels of CD3+ and CD8+ infiltrating 
lymphocytes suggesting increased tumor immunogenicity in these subtypes (56, 59). 
Additionally, other studies have shown that CD103 expression enhances retention of T 
cells in the tumor epithelium and is also associated with polarization of cytolytic granules 
(47, 67).  This then primes the T cell for cytotoxic activity once antigen recognition has 
occurred.  Although our study did not show a difference in CD8+ or CD103+ cells between 
all MSI-H and MSS EC, there was a significant difference in granzyme B+ cells and 
activated CTLs as demonstrated by colocalization of CD8 and granzyme B.  This provides 
further evidence of a more active immune microenvironment in MSI-H EC, and suggests 
that the CTLs that are present are activated and capable of mounting an anti-tumor immune 
response.  Inevitability, however, such activation is followed by exhaustion and inhibition 
via immune checkpoint expression, such as PD-L1.  
While an overall characterization of immune cell types is informative, an 
understanding of expression patterns for specific markers is also important for improved 
immunotherapy studies and clinical trials.  PD-L1 expression on tumor versus stromal cells 
may have important implications for therapeutic response to anti-PD-L1 therapies, but 
expression varies among tumor types (41, 42).   Our study found low overall expression of 
tumoral PD-L1+ cells and no difference in expression between all MSI-H and MSS EC.  
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However, we did find elevated levels of stromal cell PD-L1 expression with a significant 
increase in both all MSI-H and sporadic MSI-H versus matched MSS EC.  Additionally, 
sporadic MSI-H also showed increased tumoral PD-L1 expression versus MSS EC. 
Although many studies have focused on tumor PD-L1 expression and its ability to predict 
response to anti-PD-1 and anti-PD-L1 therapy, its role as a biomarker remains unclear (41, 
42).  Further evaluation of PD-L1 expression among tumor types prior to treatment is 
needed, as well as, in responders and non-responders following immune checkpoint 
blockade therapy.     
To further define the stromal PD-L1 expressing cells in our study, colocalization 
analysis of PD-L1 with both CD68 (macrophages) and CD11c (dendritic cells) was 
conducted.  Overall there was no difference between all MSI-H and MSS EC in the number 
of CD68 or CD11c cells positive alone, but there was an increase in those co-expressing 
PD-L1 and CD11c (PD-L1+ dendritic cells).  The sporadic MSI-H sub-analysis also 
showed an elevated number of PD-L1+ macrophages and PD-L1+ dendritic cells compared 
to MSS EC, suggesting that both macrophages and dendritic cells may be key regulators 
of immune inhibition in the sporadic MSI-H EC microenvironment.  This finding along 
with the correlation of PD-L1 expression on CD163 myeloid cells in MSI-H colorectal 
cancers, seen in other studies, suggests an alternate mechanism for immune response 
inhibition in these tumors from direct tumor cell suppression.  Other immune checkpoints 
are also likely contributing to immune suppression, as suggested by increased LAG-3 gene 
mRNA levels in MSI-H tumors from our TCGA analysis. As therapies targeting these other 
immune cell populations and immune checkpoints (i.e. TAMs and LAG-3) are becoming 
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available, additional studies are needed to further characterize these populations in MSI-H 
EC in order to expand treatment options.  
Looking more closely at the sub-analysis of sporadic MSI-H EC, sporadic MSI-H 
tumors demonstrate both increased markers of immune cell infiltration and immune 
suppression compared to MSS EC.  MSI-H EC had increased CD3+, CD4+, and PD-L1+ 
staining cell populations in both the stromal and tumor epithelial compartments compared 
to matched MSS tumors.  From these findings we can conclude that sporadic MSI-H, 
compared to MSS ECs, have increased immune cell infiltration and subsequent suppression 
of the immune response through checkpoint activation.  These findings most closely mirror 
those found in the other MSI-H EC and colorectal microenvironment studies previously 
discussed, and suggest that sporadic MSI-H EC would respond favorably to single agent 
immune checkpoint blockade.   
The role of immune checkpoint expression in LS MSI-H ECs, on the other hand, is 
less clear. Sub-analysis of LS MSI-H EC demonstrated increased CD8+ and active CTLs 
in both the stroma and tumor epithelial compartments, but no difference in PD-L1 
expression when compared to matched MSS cases.  Similar to sporadic MSI-H versus MSS 
EC analysis, LS MSI-H EC also appears to promote an immunogenic microenvironment, 
but the same PD-L1 checkpoint expression was not seen.  We can speculate that other 
immune checkpoints such as CTLA-4, TIM-3 (T cell immunoglobulin and mucin-domain 
containing-3) or LAG-3 may play a larger role in this subtype.  Further studies specifically 
evaluating the expression of CTLA-4, TIM-3, LAG-3, and other immune checkpoints 
markers are needed to more clearly define immune checkpoint activity in these tumors, and 
to draw a more complete picture of the LS MSI-H immune microenvironment in EC. 
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Additionally, in some instances single agent immune checkpoint blockade is 
insufficient to overcome immune inhibition while combination therapy is able to target 
multiple immune checkpoint pathways (65, 68).  In melanoma, combination anti-CTLA-4 
and anti-PD-1 therapy has shown particular benefit in patients with PD-L1 negative tumors 
(65). Additionally, synergistic effects of combination immune checkpoint blocking agents 
have been shown in preclinical trials of combination anti-TIM-3 or anti-LAG-3 with anti-
PD-1. Such combination therapies may provide more clinical benefit in LS MSI-H EC than 
single agent immune checkpoint blockade (69, 70). Along with this, consideration of 
combination immunotherapy and traditional cytotoxic agents may further improve 
response rates.  In non-small cell lung cancer, preliminary phase I studies have shown 
activity and tolerability of combination of immune checkpoint blockade and 
chemotherapeutic agents (71, 72).   This may be of particular importance in LS MSI-H EC 
where there is suggestion that the immune checkpoint expression is less robust.  Here 
alternative immune checkpoint blockade or combination therapies are likely required.   
Overall, this study provides new insight into the immune microenvironment related 
to MSI status in EC.  It is the largest cohort assessing the immune microenvironment of 
MSI-H EC and the first to specifically investigate LS MSI-H EC cases.  This large cohort 
was also matched to reduce confounding factors that influence immune cell populations 
and immune marker status (matched according to histology, grade, stage, age at diagnosis 
and BMI).  There may, however, be some decrease in the overall differences of positive 
cell counts seen between MSI-H and MSS EC as MSS EC cases had higher rates of LVSI 
which is a known risk factor for disease recurrence.  In addition to this unique sample set, 
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immune microenvironment characterization was more powerful due to the use of 
multiplexed IHC coupled with digital imaging for quantitation and colocalization analysis.   
This study overcomes limitations observed in previous immune cell studies in EC, 
such as evaluation of limited high powered fields and inconsistent quantitation and scoring 
strategies.  Vectra imaging and inForm software provided computer automated random 
high power field selection and counting of positively stained cells, allowing for an 
objective and uniform assessment of immunohistochemical staining.  Traditionally, 
staining quantification by IHC is limited to a few high powered fields that are chosen based 
on areas of representative staining, and it is difficult to control for interpreter bias.  In 
contrast, the true random selection of up to 30 HPFs in our study provides a more global 
reflection of the immune microenvironment of the samples, and is less likely to be biased 
by areas of sparse or concentrated staining.   Furthermore, the identification of positive 
staining thresholds and computer quantification reduces inter- and intra-observer 
variability of positive cell counting.   
It is also important to recognize the limitations of this new imaging and quantitation 
methodology.  Despite improving the objectivity of IHC analysis in our study, some 
subjective measures are still used in the process of developing these methods, such as 
determination of positive signal thresholds and lack of 100% accuracy in identifying tumor 
and stroma compartments.  Importantly, these limitations in the analysis would not be 
skewed towards any one group and would not change the trends in the immune markers 
seen. While multiplexing IHC panels empower analysis of multiple markers on a single 
tissue section, this methodology is particularly sensitive to batch effects and must be 
considered in both study design and analysis.  Comparisons of markers between groups 
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must be confined to staining within a single batch (single panel), as demonstrated by the 
differences in PD-L1 and CD8 staining intensity among the panels.  There are multiple 
reasons that may contribute to difference in staining intensity.  Different temperatures used 
in antigen retrieval for the unique antibodies used in the different panels can impact antigen 
retrieval. Specifically, elevated temperatures used in multiplexing panel 1 may have 
enhanced antigen retrieval and staining intensity resulting in the increased intensity of PD-
L1 staining in panel 1.  Additionally, the IHC staining and processing of slides in this 
method is conducted manually.  As such, there is likely to be some slight variation between 
timing across batches in any one of the 8 steps, in particular the 5 steps that are repeated 
up to 4 times.  This points to the importance of ensuring that all slides are stained together 
and that comparisons can only be made within one batch.  In this specific case, the 
consistent trend in stromal PD-L1 expression does support a difference in PD-L1 
expression between MSI-H and MSS EC.  
This study could be further improved by adding analysis of POLE mutation status 
as this EC molecular subtype has been shown to have an even more immunogenic 
microenvironment than MSI-H EC (56, 59).  As these tumors tend to be MSS, the counts 
of immune cells and immune markers in the MSS group may have been elevated and 
resulted in a smaller overall difference in positive cell counts between the two groups.  
Despite this, stratifying patients by MSI status for consideration of immune checkpoint 
blockade is the most clinically feasible as patients with POLE mutations are much less 
likely to recur.  
In considering next steps to further evaluate efficacy of immunotherapy in the MSI-
H EC patient population, a phase 2 study evaluating response rates to immune checkpoint 
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blockade in patients with MSI-H and MSS EC is needed.  A potential study design was 
created in collaboration Dr. Amir Jazaeri and is depicted in Figure 12.   Briefly, such a 
study would include patients with advanced or recurrent EC that have failed initial standard 
chemotherapy.  Patients with MSI-H tumors would make up the first arm and those with 
MSS tumors the second arm.  Treatment would begin with a single agent anti-PD-1 or anti-
PD-L1 therapy.  Anti- CTLA-4 treatment would then be added for those that progressed or 
did not respond to single agent therapy, as combination anti-CTLA-4 and anti-PD-1 has 
previously shown improved responses to single agent therapy in other tumor types (65).   
This adaptive approach would help to maximize benefit from immune checkpoint blockade 
in the entire cohort by adding a second agent for non-responders, while also identifying 
those who do respond to a single agent to minimize adverse effects from an unnecessary 
second agent.   
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Figure 12. Proposed phase 2 trial to evaluate the role of immune checkpoint 
blockade in advanced and recurrent EC.   
Abbreviations: EC, endometrial cancer; MSI-H, high microsatellite instability; MSS; 
microsatellite stable; SD, stable disease. 
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Chapter 5: Conclusions 
In summary, this thesis shows that MSI-H ECs have an altered immune 
microenvironment compared to MSS ECs.  Specifically, MSI-H EC compared to MSS EC 
demonstrated increased activation of the granzyme B pathway and elevated levels of 
activated CTLs.  This increased cytolytic activity indicates an immune related anti-tumor 
response in MSI-H EC.  Additionally, increased stromal PD-L1 expression was seen in all 
MSI-H EC versus MSS and suggests a shift to a pro-tumorigenic microenvironment and 
suppression of the immune response. As our understanding of the spectrum of patients 
benefiting from immunotherapy and immune checkpoint blockade widens, these therapies 
may prove to be advantageous in EC patients. Our finding of increased activated CTLs and 
stromal PD-L1 expression in MSI-H ECs identifies patients with this molecular subset of 
tumors as candidates for treatment with immunotherapy.   
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